The most recent numbers show that two-thirds of abortions in the U.S. are medication abortions, while 29 percent of all U.S. abortions were telehealth medication abortions. Dr. Angel Foster, researcher at the University of Ottawa in the Faculty of Health Sciences, global abortion researcher, and co-founder of the Massachusetts Medication Abortion Access Project (MAP) sits down to talk with us about the work that MAP performs and the importance of shield laws for reproductive health care and gender-affirming care.
Mifepristone, the first of two medications that people will take during a medication abortion, was approved by the U.S. Food and Drug Administration in 2000. Decades of evidence shows its safety and effectiveness. Access to the two-drug regimen increased significantly via telehealth during the pandemic, which required a new regulatory framework in 2023. MAP, through state shield law protections, allows licensed Massachusetts clinicians to prescribe medication abortion to those anywhere in the country, regardless of the legal status of abortion in their state. This year, the Fifth-Circuit Court of Appeals issued a ruling that would prevent providers from sending medication abortion through the mail—thankfully, MAP was able to shift to a misoprostol-only regimen (also safe and effective)—but the mass confusion had been immediately impactful. As of now, a stay has been issued to halt this decision by the Fifth Circuit.
For more information, check out That Aged Well: https://pod.link/1446333312
Podden och tillhörande omslagsbild på den här sidan tillhör
Jennie Wetter. Innehållet i podden är skapat av Jennie Wetter och inte av,
eller tillsammans med, Poddtoppen.
